Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.63 |
| ▸ | CHRM4 | P08173 | 16/20 | 0.63 |
| ▸ | CHRM5 | P08912 | 16/20 | 0.63 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.63 |
| ▸ | DRD2 | P14416 | 12/20 | 0.63 |
| ▸ | DRD4 | P21917 | 12/20 | 0.63 |
| ▸ | DRD3 | P35462 | 12/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.63 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.63 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6970264 | 0.99 | CHRM1 (0.61) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7605943 | 0.93 | CHRM2 (0.57) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL8198843 | 0.92 | CHRM2 (0.56) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5498886 | 0.90 | CHRM2 (0.55) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL7171361 | 0.89 | CHRM2 (0.54) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL7609200 | 0.88 | CHRM1 (0.66) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL8182585 | 0.87 | CHRM1 (0.65) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5495902 | 0.86 | SLC6A1 (0.59) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| Hydrochloric Acid SCHEMBL6971088 | 0.85 | SLC6A1 (0.58) | CHRM1CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL5500223 | 0.85 | CHRM1 (0.61) | CHRM1CHRM2CHRM4CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | claimed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | claimed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | claimed |
| US-6071901-A | TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES | NOVO NORDISK A/S (DK) | 2000-06-06 | — | — | US | claimed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | claimed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | claimed |
| US-20070066570-A1 | Methods for treating sleep disorders | HYPNION, INC. | 2007-03-22 | — | — | US | disclosed |
| EP-0820451-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | disclosed |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | LUBRIZOL CORPORATION, THE | 2002-04-18 | — | — | US | disclosed |
| EP-1135129-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2001-09-26 | — | — | EP | disclosed |
| US-6239148-B1 | TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, | NOVO NORDISK A/S (DK) | 2001-05-29 | — | — | US | disclosed |
| US-6166009-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK A/S (DK) | 2000-12-26 | — | — | US | disclosed |
| WO-2000032193-A1 | USE OF N-SUBSTITUTED AZAHETEROCYCLIC COMPOUNDS FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INDICATIONS RELATED TO ANGIOGENESIS | NOVO NORDISK A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
| US-6071901-A | TREATING PAIN, HYPERALGESIA AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A PATHOPHYSIOLOGICAL ROLE; INHIBITION OF NEUROGENIC INFLAMMATION INVOLVING THE RELEASE OF NEURO-PEPTIDE FROM PERIPHERAL AND CENTRAL ENDINGS OF SENSORY NERVES | NOVO NORDISK A/S (DK) | 2000-06-06 | — | — | US | disclosed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066570-A1 | Methods for treating sleep disorders | HCRTR2, HNMT, HCRTR1 | CHRM1 460/4885CHRM2 178/4885CHRM4 108/4885 |
| US-20020045610-A1 | Use of N-substituted azaheterocyclic compounds for the manufacture of a pharmaceutical composition for the treatment of indications related to angiogenesis | VEGFA, KDR, FLT4 | CHRM1 4192/4885CHRM2 3498/4885CHRM4 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.